News

RPC1063 is a S1P1 selective modulator, which shows picomolar potency that is effective in rodent models of both multiple sclerosis and inflammatory bowel disease and has safety profile

For the completion, the company has initiated the installation qualification (IQ) validation process through Biopharmax Group, which is handling the build-out of Pluristem’s facility. Following the successful IQ,

The new solution, BINOSTO (alendronate sodium), is intended for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. EffRx Pharmaceuticals chairman

The NDA included the data of clinical studies in more than 3,000 pregnant women at term including the EXPEDITE study. The 1,358 patient-based double blind, randomized, multicenter EXPEDITE

Tamoxifen Citrate is the most common drug prescribed to treat breast cancer. Soltamox is expected to offer treatment option for patients who need tamoxifen and also solve difficulties of

The drug is a oral soluble guanylate cyclase (sGC) stimulator which is designed to treat patients with either inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary hypertension (PH)

The solution is expected to support Tigermed’s expansion of operations into Europe and North America. Tigermed chairman and general manager Xiaoping Ye said Tigermed was seeking a CTMS

Oxtellar XR is an antiepileptic drug used as an adjunct therapy to treat partial seizures in adults and in children 6 to 17 years of age. Supernus chief

The C4C project coordinated by CELLforCURE is expected to bring together the skills of two biotech companies, seven public-sector organizations and university medical centers. Five cell therapies are